Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
2.48
Dollar change
+0.08
Percentage change
3.33
%
Index- P/E- EPS (ttm)-1.82 Insider Own20.60% Shs Outstand15.12M Perf Week11.21%
Market Cap37.50M Forward P/E- EPS next Y-1.24 Insider Trans0.00% Shs Float12.01M Perf Month-10.47%
Income-22.22M PEG- EPS next Q-0.34 Inst Own10.04% Short Float / Ratio1.47% / 3.13 Perf Quarter-32.05%
Sales0.06M P/S624.96 EPS this Y-8.62% Inst Trans10.36% Short Interest0.18M Perf Half Y-48.87%
Book/sh0.57 P/B4.32 EPS next Y23.12% ROA-104.74% Target Price8.80 Perf Year-24.62%
Cash/sh0.81 P/C3.07 EPS next 5Y- ROE-148.15% 52W Range2.00 - 6.19 Perf YTD-20.77%
Dividend- P/FCF- EPS past 5Y-99.69% ROI-276.72% 52W High-59.94% Beta0.11
Dividend %- Quick Ratio2.30 Sales past 5Y131.63% Gross Margin-41.54% 52W Low24.00% ATR0.20
Employees32 Current Ratio2.30 Sales Q/Q- Oper. Margin-40607.29% RSI (14)47.34 Volatility7.39% 7.59%
OptionableYes Debt/Eq0.14 EPS Q/Q3.15% Profit Margin-40264.62% Rel Volume1.68 Prev Close2.40
ShortableYes LT Debt/Eq0.10 EarningsNov 14 BMO Payout- Avg Volume56.47K Price2.48
Recom1.00 SMA20-0.14% SMA50-13.43% SMA200-37.86% Volume94,670 Change3.33%
Date Action Analyst Rating Change Price Target Change
Apr-12-21Initiated Oppenheimer Outperform $30
Apr-12-21Initiated BTIG Research Buy $30
Dec-04-23 08:00AM
Dec-01-23 08:00AM
Nov-29-23 08:00AM
Nov-24-23 01:01PM
Nov-22-23 11:58AM
08:54AM Loading…
Nov-21-23 08:54AM
Nov-20-23 04:03PM
Nov-14-23 07:00AM
Oct-04-23 08:45AM
07:00AM
Sep-25-23 04:05PM
Sep-20-23 04:05PM
Sep-12-23 09:25AM
Aug-29-23 08:57AM
Aug-28-23 07:00AM
08:25AM Loading…
Aug-10-23 08:25AM
07:00AM
Aug-07-23 07:00AM
Jul-31-23 08:00AM
Jun-01-23 08:00AM
May-13-23 08:09AM
May-12-23 09:15AM
08:00AM
May-08-23 10:00AM
May-03-23 09:15AM
Apr-12-23 04:30PM
Mar-29-23 08:52AM
Mar-23-23 04:05PM
Mar-22-23 08:30AM
Mar-21-23 08:00AM
08:00AM Loading…
Mar-09-23 08:00AM
Feb-27-23 08:00AM
Feb-02-23 08:00AM
Jan-17-23 10:00AM
Jan-12-23 04:05PM
Nov-10-22 05:15PM
04:02PM
Sep-26-22 11:59AM
08:00AM
Sep-20-22 07:30AM
Sep-19-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-08-22 09:15AM
08:00AM
Aug-04-22 08:00AM
Aug-03-22 10:00AM
Jun-02-22 08:00AM
May-18-22 08:00AM
May-16-22 05:55PM
04:05PM
May-11-22 09:30AM
May-06-22 08:00AM
May-03-22 08:31AM
May-02-22 03:00PM
Apr-26-22 05:19PM
Apr-12-22 01:00PM
Mar-29-22 08:00AM
Mar-24-22 08:00AM
Mar-15-22 08:00AM
Mar-01-22 08:00AM
Feb-08-22 08:00AM
Feb-04-22 12:06PM
Jan-31-22 04:05PM
Jan-18-22 08:00AM
Jan-06-22 04:05PM
Dec-28-21 04:05PM
Dec-16-21 06:57AM
Dec-07-21 08:00AM
Dec-01-21 04:07PM
Nov-12-21 09:52AM
07:00AM
Nov-11-21 11:00AM
Nov-10-21 11:00AM
Nov-04-21 04:05PM
Oct-28-21 08:00AM
Oct-26-21 08:00AM
Oct-19-21 08:00AM
Oct-12-21 10:07AM
Sep-23-21 08:00AM
Sep-17-21 08:00AM
Sep-09-21 04:20PM
Sep-08-21 03:51PM
11:42AM
09:08AM
Sep-02-21 04:05PM
Aug-11-21 04:01PM
Aug-03-21 04:05PM
Jun-21-21 05:49PM
Jun-19-21 05:49AM
Jun-10-21 07:30AM
May-27-21 08:00AM
May-17-21 08:00AM
May-10-21 04:01PM
May-03-21 07:30AM
Apr-27-21 04:01PM
Apr-22-21 08:00AM
Apr-20-21 08:00AM
Apr-14-21 09:13PM
07:00AM
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.